Talis Biomedical Corporation Operating Expenses
Talis Biomedical Corporation reported Operating Expenses of $26.35 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2022-11-03
- Talis Biomedical Corporation operating expenses for the quarter ending 2022-09-30 was $26.35M, a 31.80% decline year-over-year.
- Talis Biomedical Corporation operating expenses for the quarter ending 2022-06-30 was $26.54M, a 58.83% decline year-over-year.
- Talis Biomedical Corporation operating expenses for the quarter ending 2022-03-31 was $32.63M, a 51.67% decline year-over-year.
- Talis Biomedical Corporation operating expenses for the quarter ending 2021-12-31 was $29.38M, a 33.86% decline year-over-year.
- Talis Biomedical Corporation operating expenses for fiscal 2021 was $200.01M, a 95.85% increase from fiscal 2020.
- Talis Biomedical Corporation operating expenses for fiscal 2020 was $102.12M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2022-09-30 | $26.35M 10-Q · filed 2022-11-03 | $52.89M derived: sum of 2 quarters · filed 2022-11-03 | $85.52M 10-Q · filed 2022-11-03 | $114.90M derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | $26.54M 10-Q · filed 2022-08-02 | $59.18M 10-Q · filed 2022-08-02 | $88.55M derived: sum of 3 quarters · filed 2022-08-02 | $127.19M derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-03-31 | $32.63M 10-Q · filed 2022-05-10 | $62.01M derived: sum of 2 quarters · filed 2022-05-10 | $100.64M derived: sum of 3 quarters · filed 2022-11-03 | $165.12M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-12-31 | $29.38M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $68.01M derived: sum of 2 quarters · filed 2022-11-03 | $132.49M derived: sum of 3 quarters · filed 2022-11-03 | $200.01M 10-K · filed 2022-03-15 |
| 2021-09-30 | $38.63M 10-Q · filed 2022-11-03 | $103.11M derived: sum of 2 quarters · filed 2022-11-03 | $170.63M 10-Q · filed 2022-11-03 | $215.05M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $64.48M 10-Q · filed 2022-08-02 | $132.00M 10-Q · filed 2022-08-02 | $176.41M derived: sum of 3 quarters · filed 2022-08-02 | $215.48M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $67.52M 10-Q · filed 2022-05-10 | $111.94M derived: sum of 2 quarters · filed 2022-05-10 | $151.00M derived: sum of 3 quarters · filed 2022-05-10 | $161.85M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $44.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $83.48M derived: sum of 2 quarters · filed 2022-03-15 | $94.33M derived: sum of 3 quarters · filed 2022-03-15 | $102.12M 10-K · filed 2022-03-15 |
| 2020-09-30 | $39.07M 10-Q · filed 2021-11-16 | $49.91M derived: sum of 2 quarters · filed 2021-11-16 | $57.71M 10-Q · filed 2021-11-16 | |
| 2020-06-30 | $10.84M 10-Q · filed 2021-08-10 | $18.64M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $7.79M 10-Q · filed 2021-05-13 |